A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor. [PDF]
Heß G +6 more
europepmc +1 more source
Scedosporium Brain Abscess: A Rare and Fatal Drawback of Bruton Tyrosine Kinase Inhibitor Therapy. [PDF]
Dalmazzo M +10 more
europepmc +1 more source
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. [PDF]
Pleyer C +13 more
europepmc +1 more source
Bruton Tyrosine Kinase Inhibitor-Associated Pericardial Events by Agent and Generation.
Serra VSB +16 more
europepmc +1 more source
Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy. [PDF]
Fernandez Turizo MJ +7 more
europepmc +1 more source
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. [PDF]
Shah NN +34 more
europepmc +1 more source
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). [PDF]
Sharman JP +27 more
europepmc +1 more source
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study. [PDF]
Cooper N +17 more
europepmc +1 more source
Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies. [PDF]
Lee BJ +6 more
europepmc +1 more source

